|

homoharringtonine Clinical Trials

6 actively recruiting trials

Also known as: 6-MP, Asparaginase, Cyclophosphomide, Cytarabine, Daunorubicin +6 more

Pipeline

Phase 2: 3Phase 3: 1Phase 2/3: 2

Top Sponsors

  • baotai Liang1
  • The First Affiliated Hospital of Soochow University1
  • Shanxi Bethune Hospital1
  • Institute of Hematology & Blood Diseases Hospital, China1
  • First Affiliated Hospital of Zhejiang University1

Indications

  • Cancer6
  • Acute Myeloid Leukemia2
  • Acute T Lymphpblastic Leukemia/Lymphoma1
  • Childhood Leukemia, Acute Lymphoblastic1
  • Relapsed or Refractory Acute Myeloid Leukemia1

Other6 trials

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Phase 2
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
Phase 2
Newly-diagnosed Pediatric T-cell ALL Protocol
Phase 2/3
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Phase 3
VHAG in Treating R/R T-ALL/LBL
Phase 2
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.